150 related articles for article (PubMed ID: 25801958)
1. PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Citro S; Miccolo C; Meloni L; Chiocca S
J Mol Cell Biol; 2015 Apr; 7(2):132-42. PubMed ID: 25801958
[TBL] [Abstract][Full Text] [Related]
2. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract][Full Text] [Related]
3. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
4. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
5. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.
Yamnik RL; Digilova A; Davis DC; Brodt ZN; Murphy CJ; Holz MK
J Biol Chem; 2009 Mar; 284(10):6361-9. PubMed ID: 19112174
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.
Alayev A; Salamon RS; Berger SM; Schwartz NS; Cuesta R; Snyder RB; Holz MK
Oncogene; 2016 Jul; 35(27):3535-43. PubMed ID: 26522726
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
8. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation.
Wing LY; Chen HM; Chuang PC; Wu MH; Tsai SJ
J Biol Chem; 2005 May; 280(20):19937-47. PubMed ID: 15760907
[TBL] [Abstract][Full Text] [Related]
9. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.
Maruani DM; Spiegel TN; Harris EN; Shachter AS; Unger HA; Herrero-González S; Holz MK
Oncogene; 2012 Dec; 31(49):5073-80. PubMed ID: 22286763
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells.
De Amicis F; Giordano F; Vivacqua A; Pellegrino M; Panno ML; Tramontano D; Fuqua SA; Andò S
FASEB J; 2011 Oct; 25(10):3695-707. PubMed ID: 21737614
[TBL] [Abstract][Full Text] [Related]
11. Sumoylation of TCF21 downregulates the transcriptional activity of estrogen receptor-alpha.
Ao X; Li S; Xu Z; Yang Y; Chen M; Jiang X; Wu H
Oncotarget; 2016 May; 7(18):26220-34. PubMed ID: 27028856
[TBL] [Abstract][Full Text] [Related]
12. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
Heinonen H; Nieminen A; Saarela M; Kallioniemi A; Klefström J; Hautaniemi S; Monni O
BMC Genomics; 2008 Jul; 9():348. PubMed ID: 18652687
[TBL] [Abstract][Full Text] [Related]
13. Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.
Bratton MR; Martin EC; Elliott S; Rhodes LV; Collins-Burow BM; McLachlan JA; Wiese TE; Boue SM; Burow ME
J Steroid Biochem Mol Biol; 2015 Jun; 150():17-23. PubMed ID: 25771071
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
15. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.
Becker MA; Ibrahim YH; Cui X; Lee AV; Yee D
Mol Endocrinol; 2011 Mar; 25(3):516-28. PubMed ID: 21292829
[TBL] [Abstract][Full Text] [Related]
16. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation.
Yamnik RL; Holz MK
FEBS Lett; 2010 Jan; 584(1):124-8. PubMed ID: 19925796
[TBL] [Abstract][Full Text] [Related]
17. Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase.
Tang X; Wang L; Proud CG; Downes CP
Biochem J; 2003 Aug; 374(Pt 1):137-43. PubMed ID: 12747804
[TBL] [Abstract][Full Text] [Related]
18. Non-tumorigenic epithelial cells secrete MCP-1 and other cytokines that promote cell division in breast cancer cells by activating ERα via PI3K/Akt/mTOR signaling.
Riverso M; Kortenkamp A; Silva E
Int J Biochem Cell Biol; 2014 Aug; 53():281-94. PubMed ID: 24878609
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
20. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
